India will revisit dosage interval based on emerging data, Health News, ET HealthWorld

(PTI Photo/Kamal Kishore)

India will revisit the dosage interval for the Covishield vaccine and take appropriate action based on emerging data, N K Arora, chairperson of the working group of immunisation advisory body NTAGI, said.

Describing the Covid and vaccination situation as “very dynamic”, he said in a statement that the emerging evidence and reports regarding the efficacy of partial versus full immunisation are also under consideration.

On the decision to increase the gap between two doses of Covishield from four-six weeks to 12-16 weeks, he said the move was based on scientific decision and there was no dissenting voice among the National Technical Advisory Group on Immunisation (NTAGI) members.

“COVID-19 and the vaccination are very dynamic. Tomorrow, if the vaccine platform tells us that a narrower interval is better for our people, even if the benefit is 5-10%, the Committee will take the decision on the basis of merit and its wisdom. On the other hand, if it turns out that the current decision is fine, we will continue with it,” Arora said.

The decision to increase the gap lay in the fundamental scientific reason regarding behaviour of adenovector vaccines, a Union Health Ministry statement quoted him as telling

View More India will revisit dosage interval based on emerging data, Health News, ET HealthWorld